Sophia Genetics

BOSTON, United States and LAUSANNE, Switzerland – May 31, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three abstracts accepted for poster presentation and one for online publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. SOPHiA GENETICS and GE Healthcare will also …

SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting Read More »

Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, …

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022 Read More »

BOSTON, United States and LAUSANNE, Switzerland – May 5, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Board of Directors and a member of the Compensation Committee …

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directorsm Read More »

BOSTON, United States and LAUSANNE, Switzerland – April 26, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platforms connecting thousands of healthcare professionals and researchers across more than 70 countries. Founded …

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform Read More »

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, March 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Revenue for full year …

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results Read More »

BOSTON and LAUSANNE, Switzerland, Feb 16, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results …

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 Read More »

The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON & ALISO VIEJO, Calif., United States and LAUSANNE, Switzerland – March 14, 2022 – SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate …

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research Read More »

BOSTON, Mass, United States, LAUSANNE, Switzerland, and TAIPEI CITY, Taiwan – March 9, 2022 – SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first institution in Asia Pacific to adopt SOPHiA GENETICS’ technology to support …

BOSTON, Mass, United States, LAUSANNE, Switzerland, and TAIPEI CITY, Taiwan – March 9, 2022 –… Read More »

The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON, United States and LAUSANNE, Switzerland – FEBRUARY 24, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for …

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies Read More »

BOSTON, United States, LAUSANNE, Switzerland, and HIROSHIMA, Japan – February 22, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of …

First Japanese Institution to Utilize SOPHiA GENETICS’ Myeloid Plus Solution Read More »